Oversubscribed Retail Offer

Futura Medical PLC

07 September 2026

 

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM THE UNITED STATES, CANADA, AUSTRALIA, THE REPUBLIC OF SOUTH AFRICA, OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. PLEASE SEE THE IMPORTANT NOTICES AT THE END OF THIS ANNOUNCEMENT.

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF REGULATION (EU) 596/2014 AS IT FORMS PART OF DOMESTIC LAW IN THE UNITED KINGDOM BY VIRTUE OF THE EU (WITHDRAWAL) ACT 2018 ("UK MAR").

Unless otherwise defined, definitions contained in this announcement have the same meanings as set out in the Company's announcements dated 3 September 2026.

7 September 2026

Futura Medical plc

("Futura" or the "Company")

Oversubscribed Retail Offer

Futura Medical plc (AIM: FUM), the consumer healthcare group behind Eroxon®, that specialises in the development and global commercialisation of innovative and clinically proven sexual health products, announces that the Retail Offer on the BookBuild platform, which closed at 4:30 p.m. on Friday, 4 September 2026, was significantly oversubscribed.

Consequently, the Company, after consultation with its advisers, has upscaled the Retail Offer from the intended £150,000 and instead conditionally raised £200,000, before expenses, through the issue of 100,000,000 new Ordinary Shares of 0.2p each (the "Retail Offer Shares").  with allocations scaled back proportionately, taking into account both applicants' existing shareholdings and the number of Retail Offer Shares applied for.   As a result, the Company has conditionally raised a total of approximately £1.8 million, before expenses, pursuant to the Firm Placing, Conditional Placing, Conditional Subscription and Retail Offer.

General Meeting, Admission and Total Voting Rights

As referenced in the announcement of 3 September 2026 and the Circular dated 4 September 2026, admission of the Retail Offer shares to trading on AIM is conditional upon the passing of the Equity Funding Resolutions to be tabled at a general meeting of the Company, scheduled for 10:00 a.m. on 23 September 2026. Immediately following admission of the Firm Placing Shares to trading on AIM (the "Initial Admission"), the Company will have 639,460,530 ordinary shares of £0.002 each in issue. An announcement confirming total voting rights following issue of the Conditional Placing Shares, Conditional Subscription Shares and the Retail Offer Shares (the "Subsequent Admission"), will be released by the Company in due course. It is expected that Initial Admission will become effective and dealings in the Firm Placing Shares will commence on AIM at 8.00 a.m. on 9 September 2026 and that Subsequent Admission will become effective and dealings commence on AIM at 8.00 a.m. on 25 September 2026.

Contacts:

Futura Medical plc	Alexander Duggan Chief Executive Officer Angela Hildreth Finance Director and COO	[e-mail] [phone] www.futuramedical.com
Panmure Liberum Nominated Adviser and Joint Broker	Emma Earl, Will Goode, Mark Rogers (Corporate Finance)	[phone]
Turner Pope Investments (TPI) Ltd - Joint Broker and Retail Offer Coordinator	Guy McDougall, Andrew Thacker	[phone]
Alma Strategic Communications	Rebecca Sanders-Hewett, Sam Modlin, Sarah Peters	[phone] [e-mail]

Notes to Editors:

Futura Medical plc (AIM: FUM) is the developer of innovative, consumer-focused, sexual health products, including lead product Eroxon® and development projects WSD4000 and Eroxon® Intense. Our core strength lies in our research, development, regulatory and business development expertise in developing innovative, clinically proven, insight-led and effective products to support our customers in the growing sexual health market.

Sexual health issues are prevalent globally in both men and women. Erectile Dysfunction ("ED") impacts 1 in 5 men globally across all adult age brackets, with approximately half of all men over 40 experiencing ED and 25% of all new diagnoses being in men under 40. 60% of women experience at least one symptom of impaired sexual response or function in a twelve-month period, with only one in four women seeking professional help and remaining chronically underserved.

Eroxon®, Futura's clinically proven lead product, has been developed for the treatment of ED. The highly differentiated product, which is the only topical gel treatment for ED available over the counter and helps men get an erection fast, addresses significant unmet needs in the ED market. Multiple license or distribution partnerships are in place for Eroxon®, across major consumer markets.

WSD4000 is a project name for Futura's development female sexual health portfolio, starting with the creation of a range of topical gels under Futura's unique platform technology, specifically designed to treat symptoms of sexual dysfunction in women. There is currently no known regulatory approved OTC treatment available for impaired sexual response and function in women. WSD4000 has the potential to be an effective, breakthrough treatment for the common symptoms associated with impaired sexual response and function, such as lack of desire, arousal, lubrication, ability to orgasm and overall sexual satisfaction.

 

END